Drug Database
PR

prednisolone farnesil (Farnezone / Farnesone / Farnerate)

✓ Approved

SK · NR3C1 · Small Molecule

What is prednisolone farnesil?

prednisolone farnesil is a small molecule developed by SK. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesFarnezone, Farnesone, Farnerate
CompanySK
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, SK

Mechanism of Action

Molecular Targets

prednisolone farnesil acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

prednisolone farnesil is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved

Related Research Articles

PubMedCase reports in rheumatology2026-09-18

Dose-Escalated Upadacitinib for Refractory Myositis in Anti-Jo-1-Positive Antisynthetase Syndrome: A Case Report.

Kukida Yuji Y, Inoue Hironori H

Anti-Jo-1-positive antisynthetase syndrome (ASS) can follow a relapsing course during glucocorticoid tapering, and evidence for refractory myositis remains limited. We report a 33-year-old woman with anti-Jo-1-positive ASS with a dermatomyositis phenotype and recurrent myositis despite multiple immunosuppressants, biologics, and Janus kinase (JAK) inhibitors. Upadacitinib was increased from 15 to 30 mg/day during a flare, together with intravenous immunoglobulin and temporary prednisolone escalation. During follow-up, upadacitinib was withdrawn twice for fertility treatment; both withdrawals were followed by disease flares, and disease control was restored after reintroduction. Prednisolone was ultimately discontinued. This repeated withdrawal-rechallenge pattern suggests that dose-escalated upadacitinib may have contributed to sustained disease control.

PMID 42756780
Read full article →
PubMedRheumatology (Oxford, England)2026-09-18

Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling.

Yoshida Tsuneyasu T, Hiwa Ryosuke R, Shoji Mikihito M, Manabe Atsushi A et al.

To evaluate the association between avacopan (AVA) use and recurrent relapse and severe infection in patients with ANCA-associated vasculitis, with particular attention to time-varying treatment and glucocorticoid exposure. In this multicentre retrospective cohort study, AVA use was modelled as a time-varying exposure. Stabilized inverse probability of treatment weighting was used to adjust for baseline differences. Recurrent relapse and severe infection, defined as an infection requiring hospitalisation, were analysed using time-dependent Cox proportional hazards models based on the Andersen-Gill formulation. Exploratory models additionally incorporated time-varying and cumulative prednisolone exposure. A total of 387 patients were included, of whom 52 received AVA and 335 did not. AVA exposure was associated with a lower estimated risk of severe infection (adjusted HR 0.22, 95% CI 0.07-0.68; P = 0.008), whereas no statistically significant difference in recurrent relapse risk was observed. AVA use was also associated with lower prednisolone exposure over time. This association with severe infection remained directionally consistent in glucocorticoid-adjusted models, although its magnitude varied depending on model specification. In this multicentre real-world cohort, AVA exposure was associated with a lower estimated risk of severe infection and reduced glucocorticoid exposure, whereas no statistically significant reduction in recurrent relapse risk was observed. These findings suggest that an AVA-containing treatment strategy may be associated with improved infection-related outcomes in routine practice, although the observational design precludes causal inference.

PMID 42757695
Read full article →
PubMedNigerian medical journal : journal of the Nigeria Medical Association2026-09-18

Neuroschistosomiasis Mimicking Spinal Tuberculosis: A Case Report.

Abubakar Muhammadu Sani MS, Muazu Jabiru J, Yusuf Abdulwahab Elladan AE, Abubakar Nasir Bakiyawa NB et al.

Schistosomiasis is a chronic parasitic disease acquired through freshwater exposure, in which cercariae penetrate the skin and mature into adult worms. Disease manifestations largely result from granulomatous inflammation and fibrosis surrounding retained eggs. A 65-year-old widow presented with six months of lower back pain, weight loss, paraplegia (power 1/5), sphincter dysfunction, a T12 sensory level, and T9-T10 gibbus. She had received empirical antitubercular therapy for two months without improvement. Thoracolumbar MRI demonstrated vertebral and disc collapse at T10-T11 and L1-L2, with adjacent paravertebral abscesses and cord compression. Surgical biopsies revealed numerous calcified Schistosoma haematobium eggs with terminal spines, surrounded by granulomas containing epithelioid histiocytes, foreign-body giant cells, lymphocytes, and eosinophils. She received weekly praziquantel (1,200 mg) and tapered prednisolone. Motor power improved to 2/5, although urinary and faecal incontinence persisted. Neuroschistosomiasis should be considered in endemic regions, particularly when presumed spinal tuberculosis fails to respond to treatment. Definitive diagnosis requires careful clinicoradiological and histopathological evaluation.

PMID 42756785
Read full article →
PubMedInternal medicine (Tokyo, Japan)2026-09-16

Colonic Metastases from Lung Adenocarcinoma Detected During an Evaluation of Recurrent Diarrhea Associated with Immune-Related Colitis.

Hashimoto Naohito N, Nagai Yoshiaki Y, Cho Konjo K, Watanabe Hitomi H et al.

A 74-year-old man with advanced lung adenocarcinoma developed grade 3 diarrhea after treatment with pembrolizumab. Colonoscopy and a biopsy initially suggested immune-related adverse event colitis (irAE colitis), and the symptoms improved with corticosteroid therapy. However, grade 3 diarrhea recurred during prednisolone tapering, raising a suspicion of recurrent colitis. Radiological progression of the associated intra-abdominal lymphadenopathy was also observed. Repeat colonoscopy before infliximab administration revealed multiple colonic metastases from lung adenocarcinoma. Gastrointestinal metastases should be considered in patients with atypical clinical or radiological findings, and repeated endoscopic evaluations may be useful before escalating immunosuppressive therapy.

PMID 42749653
Read full article →
PubMedCureus2026-09-16

Refractory Amiodarone-Induced Thyrotoxicosis Requiring the Consideration of Thyroidectomy: A Case Report and Review of Management Challenges.

Yunas Hishaam A HA, Mahajan Lakshey L, Lwin Khine Wut Yee KWY, Syeda Shehr B SB

Amiodarone-induced thyrotoxicosis (AIT) is an uncommon but clinically significant complication of amiodarone therapy that may be associated with substantial morbidity, particularly in patients with underlying cardiovascular disease. We report the case of a 61-year-old gentleman with a history of atrial fibrillation, ischaemic heart disease, heart failure, and obesity, who developed severe thyrotoxicosis after approximately 3.5 years of amiodarone treatment. Routine thyroid function monitoring showed stable thyroid levels for three years; however, despite an abnormality identified at a later stage, the patient remained asymptomatic. Shortly after, he was admitted with vomiting, abdominal discomfort, poor mobility, weight loss, and a free thyroxine (fT4) level exceeding 100 pmol/L. Carbimazole therapy was initiated, but persistent thyrotoxicosis necessitated dose escalation, discontinuation of amiodarone, and commencement of prednisolone for suspected AIT. During a subsequent admission, the patient developed euglycaemic diabetic ketoacidosis and later steroid-induced diabetes, requiring treatment and both diabetic and endocrine team involvement. Thyroid ultrasound demonstrated normal-low vascularity without focal abnormalities, and thyroid autoantibodies were negative. Although thyroid function tests initially improved with combined medical therapy, biochemical response later plateaued with a fT4 level of 52 pmol/L at the end of month 8, prompting referral for thyroidectomy. This case describes a challenging presentation of AIT with an incomplete response to conventional medical management and progression to consideration of definitive surgical treatment.

PMID 42746021
Read full article →
PubMedInflammopharmacology2026-09-16

Properties of Persea americana Mill (Lauraceae) kernels aqueous extract on acetic acid-induced ulcerative colitis in rats.

Gaffo Estelle Flora EF, Zahara Magni Sadi Debsoua MSD, Ngachili Chinda Larissa Vianney LV, Djiogue Sefirin S et al.

Ulcerative colitis is a chronic inflammatory bowel disease characterized by uncontrolled inflammation of the gastrointestinal tract, which is difficult to treat. The aim of this study was to evaluate the effects of Persea americana kernels aqueous extract on acetic acid-induced ulcerative colitis in rats. Thirty-six (36) male and female rats, divided into six (6) groups of six (6) rats each, were anesthetized with a ketamine (50 mg/kg)/valium (10 mg/kg) mixture after eighteen (18) hours of fasting with free access to water. Colitis was induced by the intrarectal administration of 1 mL of acetic acid (4%) in all animals except the control group, which received 1 mL of distilled water. Five (5) hours later, the normal control and the colitis control received distilled water (1 mL/kg), the positive control received prednisolone (20 mg/kg), and the three other groups received Persea americana kernels aqueous extract at 100, 200, and 400 mg/kg for seven (7) days. During treatment, stool quality and changes in body weight were assessed. At the end of treatment, the animals were anesthetized and then sacrificed. The colon, liver, spleen, kidneys, heart, lungs, and blood were collected for the analysis of inflammatory and hematological parameters. During treatment, the Persea americana extract reduced the number of diarrheal stools and maintained a nearly constant weight change. Persea extract significantly reduced (P ≤ 0.01) MPO activity, interleukin-6 levels, and TNFα. Based on these results, the aqueous extract of Persea americana kernel possesses anti-inflammatory and antioxidant effects and could therefore be used in the treatment of chronic inflammatory bowel diseases.

PMID 42745107
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about prednisolone farnesil